Company: PGEN
Filing Date: 2025-08-19
Form Type: S-3
Source: 0000950103-25-010472
Chunk: 5

Company: PRECIGEN, INC.
Filing Date: 2025-08-19
Form: S-3
Chunk 5
---
 Because it is only a summary, it does not contain all of the information that you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus, any applicable free writing prospectus and the documents incorporated by reference herein and therein. You should read all such documents carefully, especially the risk factors and our consolidated financial statements and the related notes included or incorporated by reference herein or therein, before deciding to buy our securities.

Company Overview

We are a dedicated discovery and clinical-stage
biopharmaceutical company advancing the next generation of gene and cell therapies with the overall goal of improving outcomes for patients
with significant unmet medical needs. We are leveraging our proprietary technology platforms to develop product candidates designed to
target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
We have developed an extensive pipeline of therapies across multiple indications.

We believe that our array of technology platforms
uniquely positions us among other biotechnology companies to advance precision medicine. Precision medicine is the practice of therapeutic
product development that takes into account specific genetic variations within populations impacted by a disease to design targeted therapies
to improve outcomes for a disease or patient population. Our proprietary and complementary technology platforms provide a strong foundation
to realize the core promise of precision medicine by supporting our efforts to construct powerful gene programs to drive efficacy, deliver
these programs through viral, non-viral, and microbe-based approaches to drive lower costs, and control gene expression to drive safety.
Our therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to allow us to precisely control
the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells
to treat underlying disease conditions. We have developed a proprietary electroporation device, UltraPorator, designed to further streamline
and ensure the rapid and cost-effective manufacturing of UltraCAR-T therapies. UltraPorator has received Food and Drug Administration
(“FDA”) clearance for manufacturing UltraCAR-T cells in clinical trials, and we have dosed patients with UltraCAR-T cells
manufactured with UltraPorator in our clinical trials.

Our clinical pipeline includes PRGN-2012 and PRGN-2009,
which are based on our AdenoVerse immunotherapy platform; and PRGN-3005, PRGN-3006 and PRGN-3007, which are built